Eliaz Therapeutics Industries
-
Clinical Services
-
-
-
The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibrosis that can be induced by circulating gal-3.
Therapeutic apheresis works to remove degenerative, pro-cancer and pro-inflammatory compounds that contribute to the progression of life-threatening illness— allowing the body a chance to deeply detoxify, while enhancing the effects of other therapies and supporting optimal healing.
A system and method for the practice of apheresis employs modules in the system which can be selected for a particular patient to treat particular situations or combinations of difficulties. In one example, Gal-3 mediates a large number of body reactions, and is an effective protector of tumor microenvironments and the like, as well inflammation driver.